Abstract Number: 2778 • 2019 ACR/ARP Annual Meeting
Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort…Abstract Number: 573 • 2019 ACR/ARP Annual Meeting
Identification of Factors Associated with Magnetic Resonance Images Changes Suggestive of Axial Spondyloarthritis in the Axial Skeleton of Individuals < 45 Years – Evaluation of Data from a Large Community Study
Background/Purpose: Active (bone marrow edema, BME) and structural (fatty lesions, FL) lesions in the spinal and the sacroiliac joints (SIJ), as assessed by magnetic resonance…Abstract Number: 607 • 2019 ACR/ARP Annual Meeting
Expansion of Peripheral Cytotoxic T Cells in Co-morbid Inflammatory Bowel Disease and Spondyloarthritis
Background/Purpose: Background: The clinical overlap of axial spondyloarthritis (axSpA) and Crohn’s disease (CD) has given rise to the hypothesis that these conditions may share pathophysiologic…Abstract Number: 854 • 2019 ACR/ARP Annual Meeting
Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Background/Purpose: Smoking and systemic inflammation have been shown to independently associate with radiographic spinal progression in patients with axSpA. Evidence suggests that certain socioeconomic (SE)…Abstract Number: 1492 • 2019 ACR/ARP Annual Meeting
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
Background/Purpose: Upadacitinib, a selective inhibitor of Janus kinase 1 (JAK1), is currently being evaluated for the treatment of several autoimmune disorders, including axial spondyloarthritis (axial…Abstract Number: 1551 • 2019 ACR/ARP Annual Meeting
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of…Abstract Number: 2779 • 2019 ACR/ARP Annual Meeting
Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors
Background/Purpose: The association between disease activity and spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) has been previously shown in a cohort of patients (pts)…Abstract Number: 577 • 2019 ACR/ARP Annual Meeting
Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients
Background/Purpose: Disease activity in axial spondyloarthritis (axSpA) is often quantified by the Ankylosing Spondylitis Disease Activity Score (ASDAS), a composite index which combines 4 patient…Abstract Number: 608 • 2019 ACR/ARP Annual Meeting
Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls
Background/Purpose: Enthesitis is one of the features of ankylosing spondylitis (AS). High prevalence of structural and inflammatory ultrasound lesions of peripheral entheses are found in…Abstract Number: 856 • 2019 ACR/ARP Annual Meeting
MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?
Background/Purpose: Low grade bone marrow edema (BME) on magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ) is challenging the discrimination between patients with early…Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…Abstract Number: 1778 • 2019 ACR/ARP Annual Meeting
Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis
Background/Purpose: Enthesitis is characterized by inflammation at the interface where tendon or ligament attaches to the bone and is a representative symptom of ankylosing spondylitis(AS).…Abstract Number: 579 • 2019 ACR/ARP Annual Meeting
Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?
Background/Purpose: Uveitis, psoriasis and inflammatory bowel disease (IBD) are common in axial spondyloarthritis (axSpA) but data on their impact on activity of musculoskeletal manifestations and…Abstract Number: 609 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort
Background/Purpose: There is still a debate concerning the concept of non-radiographic (nr-axSpA) axial Spondyloarthritis (e.g. to consider it as a distinct entity from r-axSpA (Ankylosing…Abstract Number: 935 • 2019 ACR/ARP Annual Meeting
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study
Background/Purpose: Acute anterior uveitis (AAU), inflammation of the anterior uveal tract, is the most common extraarticular manifestation in patients (pts) with axial spondyloarthritis (axSpA), reported…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 16
- Next Page »